Streptococcus dysgalactiae: Causes, Infections & Treatment

Streptococcus dysgalactiae is a bacterium that comes in two forms: one primarily infects animals, and the other is an increasingly common cause of human disease, from mild skin infections to life-threatening bloodstream invasions. The human-associated subspecies, known as S. dysgalactiae subsp. equisimilis (SDSE), has been climbing in clinical importance over the past two decades. Its rate of invasive disease now approaches that of its better-known relative, Streptococcus pyogenes, the bacterium behind strep throat and scarlet fever. Yet SDSE receives far less public attention, which matters because the people it hits hardest tend to already be medically vulnerable.

Two Subspecies, Two Hosts

When clinicians and researchers say “Streptococcus dysgalactiae,” they could mean one of two distinct subspecies, and the distinction matters. A formal taxonomic study in the 1990s proposed splitting S. dysgalactiae based on where the strains come from and what they do. The subspecies dysgalactiae (SDSD) is primarily an animal pathogen, most commonly found in cattle, where it causes udder infections (mastitis) that lead to significant losses in dairy production worldwide.¹ The subspecies equisimilis (SDSE) is the one that infects humans. SDSD strains belong to Lancefield serogroups C and L, while SDSE strains belong to groups C and G, are beta-hemolytic, and can break down human blood-clotting proteins.²

In practical terms, if you are reading about S. dysgalactiae in the context of human medicine, the bacterium in question is almost always SDSE. Human infections caused by the animal subspecies SDSD are extraordinarily rare: as of one case report, only three cases had been documented in the medical literature, including one instance of cellulitis and bloodstream infection in a woman with no known animal exposure.³ For the rest of this article, most discussion of human disease refers to SDSE unless stated otherwise.

What Infections Does It Cause

SDSE can cause a wide range of problems, from superficial skin infections to conditions that can kill within hours. The most common presentations are cellulitis (a spreading skin infection), wound infections, and pharyngitis (sore throat). Bacteremia, where the bacterium enters the bloodstream, is also well documented and often accompanies more severe disease.⁴ At the severe end of the spectrum, SDSE can trigger necrotizing fasciitis (the “flesh-eating” soft tissue infection) and streptococcal toxic shock syndrome, both of which carry high mortality rates.⁵

Case reports have also documented rarer manifestations, including septic arthritis (joint infection), endocarditis (infection of heart valves), and primary muscle infections even in people with otherwise healthy immune systems.⁴ That last point surprises many clinicians, because invasive SDSE infections have traditionally been thought of as diseases that hit immunocompromised or elderly patients. While that is true as a trend, it is not an absolute rule.

How It Compares to Strep Pyogenes

One reason SDSE has flown under the radar is that it lives in the shadow of its cousin Streptococcus pyogenes, commonly known as group A strep (GAS). GAS is responsible for strep throat, rheumatic fever, and most cases of necrotizing fasciitis that make headlines. SDSE and GAS share the same body niches (skin, throat) and a remarkable amount of genetic material. Molecular analysis shows that the two species share gene variants across several core housekeeping genes, so much so that trying to distinguish them using a single gene’s sequence can produce wrong answers.⁶

This genetic overlap is not just a laboratory curiosity. Both organisms swap genetic material through horizontal gene transfer, including mobile genetic elements carrying antibiotic-resistance genes and virulence genes. A community-based genomic study found nearly identical cross-species mobile genetic elements in about one in five SDSE isolates and roughly one in fourteen S. pyogenes isolates from the same population.⁷ The practical implication is that studying and controlling one of these pathogens without paying attention to the other may be incomplete. Some researchers have argued that surveillance programs for streptococcal disease should track both organisms together.⁷

How It Causes Harm

SDSE has an arsenal of tools that let it invade tissue, evade the immune system, and cause damage. Like GAS, it produces M protein on its surface, which helps it dodge white blood cells. It also makes streptolysin O and streptolysin S, toxins that punch holes in host cells, as well as enzymes like streptokinase (which dissolves blood clots to help the bacterium spread), hyaluronidase (which breaks down the “glue” between cells in tissue), and C5a peptidase (which blocks a key immune-signaling molecule).⁸ Certain strains also carry the gene for superantigen G, a protein that can trigger a massive, dangerous overreaction of the immune system, which is the mechanism behind toxic shock syndrome.⁹

Research into what tips an SDSE strain from causing a mild skin infection to causing toxic shock has pointed to mutations in certain regulatory genes. One gene called csrS normally acts as a brake on the production of streptolysin O. When mutations knock out this brake, the bacterium becomes more aggressive. A study of strains from patients with streptococcal toxic shock found csrS mutations in about a fifth of them, while non-invasive strains did not carry these mutations. A separate regulatory gene, srrG, when mutated, was associated with increased production of streptolysin S and greater virulence in animal models.¹⁰ In other words, even within SDSE, not all strains are equally dangerous, and specific genetic changes can make a strain far more lethal.

Who Is Most at Risk

Invasive SDSE disease is strongly linked to older age and underlying health conditions. A population-based study found that diabetes carried roughly a fivefold increase in the odds of SDSE bloodstream infection, obesity about a threefold increase, and coronary artery disease also about a threefold increase.¹¹ Norwegian data on necrotizing soft tissue infections echoed this pattern: patients with group C and G streptococcal infections were older and had more underlying conditions than those infected with GAS, and their infections tended to be more superficial anatomically.¹²

When it comes to outcomes once a person develops SDSE bacteremia, the cumulative burden of chronic disease matters greatly. A study found that patients with a high comorbidity burden had more than a fourfold increased risk of dying. Specific conditions tied to worse outcomes included cerebral infarction (stroke history), chronic obstructive pulmonary disease, and leukemia.¹³ Skin breaks of any kind, whether from chronic wounds, eczema, or surgical sites, are a common entry route for the bacterium. For people with diabetes or peripheral vascular disease, whose skin is already more vulnerable to breakdown and slower to heal, this creates a compounding problem.

Rising Incidence

SDSE is not a new pathogen, but the frequency of severe infections appears to be climbing. A nationwide Danish study covering 2014 to 2024 found that invasive SDSE incidence rose significantly over that period, peaking in 2023 with rates between about 10 and 16 per 100,000 people per year. The increase was especially pronounced in males and older age groups.¹⁴ Similar upward trends have been reported elsewhere. Whether this reflects genuine biological changes in the bacterium, better diagnostic detection, an aging population with more comorbidities, or some combination of all three remains an open question. One factor that likely plays a role is the sheer genetic dynamism of SDSE: horizontal gene transfer continually reshuffles its virulence toolkit.¹⁵

Diagnosis Can Be Tricky

Identifying SDSE in the laboratory is not always straightforward. The bacterium looks similar to both S. pyogenes and S. canis (a streptococcal species of dogs) under certain diagnostic methods. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-ToF MS) is a rapid identification technology now used in most clinical microbiology labs. But before targeted improvements to its reference database, MALDI-ToF correctly identified only about 62% of S. dysgalactiae isolates to the species level, with many being flagged ambiguously as either S. dysgalactiae, S. pyogenes, or S. canis. Removing just three misleading reference spectra from the database improved the identification rate to 94%.¹⁶

Why does accurate identification matter beyond academic interest? Because treatment decisions, epidemiological tracking, and infection-control responses all depend on knowing which organism you are dealing with. An SDSE infection misidentified as GAS gets lumped into the wrong category in surveillance data, distorting our understanding of both pathogens. And because SDSE and GAS have different typical patient populations and prognostic profiles, getting the name right helps clinicians calibrate their expectations.

Treatment and Antibiotic Susceptibility

The good news is that penicillin remains effective against SDSE. Penicillin and closely related beta-lactam antibiotics are the standard first-line treatment. A Japanese study testing 85 clinical isolates found every single one susceptible to penicillin G.¹⁷ This high susceptibility appears consistent across geographies. A Chinese study of 31 invasive isolates also found 100% susceptibility to penicillin, cefotaxime, and levofloxacin.¹⁸ Penicillin is adequate under most circumstances, though treatment failure does occasionally occur, and severe infections like necrotizing fasciitis typically require both aggressive antibiotics and surgical intervention.¹⁹

For patients allergic to penicillin, the picture gets more complicated. Macrolides like erythromycin and lincosamides like clindamycin are commonly used alternatives, but resistance to these drugs in SDSE is substantial. The Chinese study above found erythromycin resistance of about 87% and clindamycin resistance of about 74% among invasive isolates.¹⁸ A Taiwanese study found lower but still concerning rates: about 24% resistance to erythromycin and 12% to clindamycin.²⁰ Resistance rates clearly vary by region, but the takeaway is the same everywhere: if penicillin is not an option, susceptibility testing is essential before relying on macrolide or clindamycin therapy.

Clindamycin is worth discussing specifically because it is often added to the treatment of severe streptococcal infections like necrotizing fasciitis or toxic shock, not to kill the bacteria directly but because it can suppress toxin production. This makes it a useful adjunct even when penicillin is the primary killing agent. However, resistance rates in SDSE mean that lab confirmation of susceptibility should not be skipped.

Biofilm and Persistent Infections

One area of growing interest is biofilm formation by SDSE. Biofilms are structured communities of bacteria coated in a protective matrix that makes them much harder for antibiotics and the immune system to reach. Research has shown that bacterial aggregations consistent with biofilms are present in SDSE necrotizing soft tissue infections. Interestingly, streptokinase, one of the bacterium’s own enzymes, appears to work against biofilm formation. When researchers deleted the streptokinase gene from an SDSE strain, the bacterium’s capacity to form biofilms increased. Conversely, adding streptokinase early in the growth process prevented biofilm formation in some strains.²¹ This is a genuinely surprising finding, because it suggests that one of the bacterium’s virulence factors (streptokinase helps it spread by dissolving clots) may simultaneously work against another survival strategy (biofilm formation). Whether this trade-off has clinical implications is still being worked out.

Post-Infection Immune Complications

Like its relative GAS, streptococcal infection can sometimes trigger post-streptococcal glomerulonephritis (PSGN), a kidney condition that appears days to weeks after the original infection. In PSGN, the immune system’s response to streptococcal proteins inadvertently damages the tiny filtering units in the kidneys through the formation of immune complexes that deposit in glomerular tissue. The condition is mainly seen after GAS skin or throat infections and is now most common in economically disadvantaged communities.²² Because SDSE shares many of the same virulence proteins, including some of the nephritogenic antigens implicated in PSGN, the potential for similar post-infection complications exists, though the evidence specifically tying SDSE to PSGN is less extensive than for GAS.

The Veterinary Side and Genetic Boundaries Between Hosts

While SDSE is the human pathogen and SDSD is the animal pathogen, the boundary between them is not perfectly sealed. In cattle, SDSD is one of the major causes of mastitis. A Norwegian study of dairy herds found SDSD widely distributed in freestall environments, with risk factors including specific flooring types, rubber mats in resting areas, and parlor-style milking. The bacterium was found not only in infected udders but also in wounds, skin surfaces, and cubicle bases, suggesting the barn environment plays a meaningful role in cow-to-cow transmission.²³

Genomic studies have examined whether host boundaries are reflected at the genetic level. Analysis of surface proteins called Alp (alpha-like proteins) across hundreds of S. dysgalactiae strains found that the distribution of specific alp gene variants correlated with host species. For example, one variant (alp3) was found only in human-origin SDSE strains, while another (dysalp4) was exclusively detected in animal strains, mostly bovine SDSD. Overall, alp genes were detected in about 18% of human SDSE strains and 10–15% of animal strains.²⁴ These host-specific genetic signatures reinforce the idea that while the two subspecies share a species name, they have adapted to different hosts over evolutionary time. The rare cases of SDSD infecting humans, like the Houston case mentioned earlier, are exceptions rather than an emerging trend of zoonotic crossover, at least based on current evidence.

Vaccines and Future Directions

There is no vaccine currently available against SDSE, and research remains in early stages. Part of the challenge is the sheer genetic diversity of SDSE strains, particularly in the emm gene that encodes the M protein on the bacterial surface. M protein is a logical vaccine target because it plays such a central role in immune evasion, but the number of distinct emm types across SDSE populations is large. The Chinese isolate study, for instance, found stG245.0 and stG840.0 as the most common emm types in those particular strains, each strongly linked to specific clonal lineages.¹⁸ A vaccine targeting a handful of M protein types might miss a large proportion of circulating strains. Some vaccine approaches have explored non-M-protein targets, including components of the bacterial cell wall like rhamnose polysaccharides, which are shared across both SDSE and GAS and could theoretically offer cross-species protection. But this work remains preclinical.

The broader trajectory of SDSE research is moving toward integrated surveillance with GAS. Because the two organisms share the same body sites, swap genetic material, and cause overlapping diseases, treating them as entirely separate entities makes less epidemiological sense than it might seem. A coordinated approach to monitoring, studying resistance patterns, and eventually developing vaccines for both pathogens together may be the most practical path forward, particularly in communities where streptococcal disease burden is already high.⁷